Evogene Ltd. (NASDAQ:EVGN) Short Interest Down 15.4% in March

Evogene Ltd. (NASDAQ:EVGN) was the recipient of a large drop in short interest in March. As of March 15th, there was short interest totalling 28,100 shares, a drop of 15.4% from the February 28th total of 33,200 shares. Based on an average daily volume of 35,800 shares, the short-interest ratio is currently 0.8 days. Approximately 0.5% of the shares of the stock are sold short.

Evogene Stock Performance

EVGN stock traded up $0.01 during trading on Wednesday, hitting $1.26. The stock had a trading volume of 3,348 shares, compared to its average volume of 89,082. Evogene has a 1-year low of $1.20 and a 1-year high of $9.00. The stock has a market cap of $6.76 million, a price-to-earnings ratio of -0.28 and a beta of 1.28. The company’s 50 day moving average price is $1.45 and its two-hundred day moving average price is $1.81.

Evogene (NASDAQ:EVGN) last announced its earnings results on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.78. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%. The firm had revenue of $1.61 million for the quarter, compared to analyst estimates of $3.63 million. During the same quarter last year, the business earned ($1.30) earnings per share.

Analyst Ratings Changes

Several research firms have weighed in on EVGN. StockNews.com initiated coverage on Evogene in a report on Wednesday, March 26th. They issued a “sell” rating on the stock. Alliance Global Partners reissued a “buy” rating on shares of Evogene in a research note on Friday, March 7th.

Hedge Funds Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Citadel Advisors LLC acquired a new position in shares of Evogene Ltd. (NASDAQ:EVGN) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned 0.30% of Evogene at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.